Interactive presentation
My Journey to a Lupus Diagnosis: Advice for People Who are Newly Diagnosed
We will hear from Resa as she shares her journey starting when symptoms began to her diagnosis of lupus, providing her perspectives and advice for others who may be experiencing a similar situation.
Interactive presentation
Hey Doc, What Do You Know About SLE? Hear a Patient’s Perspective
The diagnosis of systemic lupus erythematosus can be shocking and life-changing. We will hear from Resa, a 28-year-old woman, who shares her experiences overcoming the challenges associated with diagnosis and long-term management of her disease, highlighting the importance of a positive patient-clinician relationship.
Suggested Readings
Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Choi MY, et al. Ann Rheum Dis. 2022. [E-pub ahead of print.]
Association of a combination of healthy lifestyle behaviors with reduced risk of incident systemic lupus erythematosus.
Choi MY, et al. Arthritis Rheumatol. 2022;74(2):274-283.
Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2021;80(1):14-25.
Two-year, randomized, controlled trial of belimumab in lupus nephritis.
Furie R, et al. N Engl J Med. 2020;383(12):1117-1128.
Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries.
Izmirly PM, et al. Arthritis Rheumatol. 2021;73(6):991-996.
All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.
Moghaddam B, et al. Rheumatology. 2021;61(1):367-376.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Rovin BH, et al. Lancet. 2021;397(10289):2070-2080.
SLE mortality remains disproportionately high, despite improvements over the last decade.
Singh RR, Yen EY. Lupus. 2018;27(10):1577-1581.
Linked Resources
Classification Criteria
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.
Aringer M, et al. Arthritis Rheumatol. 2019;71(9):1400-1412.
Disease Management Guidelines
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Fanouriakis A, et al. Ann Rheum Dis. 2019;78(6):736-745.
Patient Resources
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Related activities
POC101
0.25 CME/CE
Evaluating the Patient with SLE
Module 1
Faculty: | Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH |
Release: | 04/29/2022 |
Expiration: | 04/29/2023 |
POC101
0.25 CME/CE
Targeted Treatment Options for SLE
Module 3
Faculty: | Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH |
Release: | 05/30/2022 |
Expiration: | 05/30/2023 |
POC101
0.25 CME/CE
Real-World Strategies for Managing Moderate-to-Severe SLE
Module 2
Faculty: | Ashira D. Blazer, MD, MSCI; Karen H. Costenbader, MD, MPH |
Release: | 05/16/2022 |
Expiration: | 05/16/2023 |